Canada markets open in 8 hours 53 minutes

Valneva SE (VLA.VI)

Vienna - Vienna Delayed Price. Currency in EUR
Add to watchlist
5.06-0.71 (-12.31%)
At close: 05:32PM CEST
Full screen
Previous Close5.77
Open5.34
Bid5.02 x 50000
Ask5.09 x 81200
Day's Range5.06 - 5.35
52 Week Range2.06 - 5.35
Volume1,794
Avg. Volume14,123
Market Cap455.476M
Beta (5Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

    Saint Herblain (France), September 28, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, today announced its intention to issue and sell, subject to market conditions, approximately $40 million of its ordinary shares in a global offering to specified categories of investors comprised of (i) a public offering of its American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States (the “U.S. Offering”) and (ii) a con

  • Zacks

    Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why

    Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

  • Reuters

    UPDATE 2-Valneva in talks with potential partner on second-gen COVID-19 vaccines

    French drugmaker Valneva said on Monday it is in talks with a potential partner on producing an updated version of its COVID-19 vaccine that targets new variants of the disease, sending its shares up. Valneva has won regulatory approval in the European Union and some other countries for its first-generation vaccine, but said it has suspended manufacturing in light of low order levels. "Market expectations have been that the company would be winding down its COVID-19 vaccine activities, hence the bounce...", said Rx Securities Managing Director Samir Devani, adding that he advised investors to consider any COVID-19 activities as an upside option for the stock.